

Cerebral metabolic impairment in patients with obstructive sleep apnoea: an independent association of obstructive sleep apnoea with white matter change

M Kamba, Y Inoue, S Higami, Y Suto, T Ogawa, W Chen

Abstract

Objectives—To determine the relation between severity of obstructive sleep apnoea (OSA) and degree of cerebral metabolic impairment.

Methods—Fifty five patients with habitual snoring and excessive daytime sleepiness underwent standard overnight polysomnography and magnetic resonance spectroscopy separately. Proton MR spectra were measured with two dimensional chemical shift imaging (repetition time; 1500 ms, echo time; 135 ms). Severity of cerebral metabolic impairment was assessed by the *N*-acetylaspartate (NAA)/choline ratios for the cerebral cortex and white matter. Severity of OSA was assessed by the apnoea-hypopnoea index (AHI) and the minimum value of peripheral oxyhaemoglobin saturation. All patients were evaluated for the presence or absence of comorbidities including hypertension, cardiac disease, diabetes mellitus, and hyperlipidaemia. Univariate analysis of variance (ANOVA) and multiple linear regression analysis were used for statistical analyses.

Results—Univariate ANOVA disclosed significant effects of AHI, age, and the presence or absence of hypertension on the NAA/choline ratio for cerebral white matter ($p=0.011$, $p=0.028$, $p=0.0496$, respectively). The AHI had a significant negative association with the NAA/choline ratio for cerebral white matter, independent of age and the presence or absence of cardiac disease, in the final multivariate regression model (standardised partial regression coefficient= -0.417 , $p<0.001$). No significant relation was found between severity of OSA and the NAA/choline ratio for the cerebral cortex. Age alone had a significant effect on the NAA/choline ratio for the cerebral cortex on univariate ANOVA ($p<0.001$) and a significant negative association with the NAA/choline ratio for the cerebral cortex in the regression model ($r=-0.552$, $p<0.001$). **Conclusions**—A significant relation exists between AHI and the degree of metabolic impairment in cerebral white matter in patients with OSA.

(*J Neurol Neurosurg Psychiatry* 2001;71:334–339)

Keywords: magnetic resonance spectroscopy; sleep apnoea syndromes; white matter disease

Repeated sleep apnoeic episodes may lead to CNS impairment in patients with obstructive sleep apnoea (OSA). Excessive daytime sleepiness and cognitive and emotional deficits are common daytime symptoms of OSA.^{1–6} A multiple sleep latency test and maintenance of wakefulness test have been used to quantify daytime sleepiness.^{7,8} Neuropsychological and electrophysiological tests have been used to quantify cognitive dysfunction.^{1–6,9–11} Hypoxic brain damage and fragmentation of sleep are generally thought to be causes of these deficits.^{2–6,8,9}

Magnetic resonance spectroscopy (MRS) enables non-invasive evaluation of focal metabolic changes in various conditions affecting the CNS. We previously reported cerebral metabolic changes in patients with OSA.¹² The *N*-acetylaspartate (NAA)/choline ratio for cerebral white matter was significantly lower in patients with moderate to severe OSA than in patients with mild OSA and healthy subjects, indicating axonal injury or gliosis in those with the severe form.^{13–15} Our results of MRS examination during sleep disclosed lactate production, indicating that hypoxia is causing anaerobic glycolysis in the brain of patients with moderate to severe OSA.¹⁶ Our previous results suggested that a relation exists between severity of OSA and the degree of cerebral metabolic change. Patients with OSA often have several comorbidities including hypertension and other cardiovascular diseases, diabetes mellitus, and hyperlipidaemia, which are generally thought to be cerebrovascular risk factors.^{17–19} These comorbidities may promote cerebral ischaemia, and play a part in the occurrence of cerebral metabolic change. Aging is also thought to be related to cerebral metabolic change.²⁰ The aims of this study were to investigate which of these factors is significantly related to cerebral metabolic change and to determine the usefulness of MRS as an objective method for evaluation of CNS impairment in patients with OSA.

Methods

PATIENTS

All patients were recruited at the Sleep Disorder Clinic of Tottori University Hospital. Medical records of potential participants were collected on enrollment. Those with a history of CNS diseases or medical conditions contraindicating MRS such as the presence of a cardiac pacemaker were excluded from the study. Patients who had undergone tracheostomy were also excluded. Sixty three patients

Center for Magnetic Resonance Research, University of Minnesota Medical School, 2021 6th Street SE, Minneapolis, MN 55455, USA
M Kamba
W Chen

Department of Radiology, Tottori University Faculty of Medicine, 36-1 Nishi-machi, Yonago 683-8504, Japan
M Kamba
Y Suto
T Ogawa

Department of Neuropsychiatry
Y Inoue

Department of Otorhinolaryngology
S Higami

Correspondence to:
Dr M Kamba
masayuki@cmrr.umn.edu

Received 22 November 2000
and in revised form
26 March 2001
Accepted 2 April 2001

(55 men and eight women; age 22-75 years, mean 49.13 (SD 13.89) years) with habitual snoring and excessive daytime sleepiness under-
went diagnostic polysomnography and MRS in our hospital. All patients were clinically evaluated for the presence or absence of comorbidities including hypertension, cardiac disease, diabetes mellitus, and hyperlipidaemia. Antihypertensive treatment at the time of enrollment or systolic blood pressure greater than 160 mm Hg or diastolic blood pressure greater than 95 mm Hg on two independent visits was considered evidence of hypertension. A history of documented ischaemic heart disease or abnormal ECG exhibiting ischaemic changes, left ventricular hypertrophy, or arrhythmia was considered evidence of cardiac disease. Antidiabetic treatment at the time of enrollment or fasting blood glucose concentration of 140 mg/dl or greater was considered evidence of diabetes mellitus. Treatment for hyperlipidaemia at the time of enrollment or total cholesterol concentration of 240 mg/dl or more was considered evidence of hyperlipidaemia. The body mass index (weight (kg)/height² (m)) of each patient was determined at the time of polysomnographic examination. None of the patients had congenital metabolic abnormalities affecting the CNS. After complete description of the study to the patients, written informed consent was obtained in accordance with the Declaration of Helsinki.

DIAGNOSTIC POLYSOMNOGRAPHY

Standard overnight polysomnography was performed for each patient within 3 months before the MRS study. Sleep state was monitored by EEG, electro-oculography, and submental EMG. Air flow in the nasal and oral cavities was monitored with thermistors. Thoracoabdominal respiratory motion was monitored with strain gauges. Arterial oxygenation was monitored with a Biox II finger pulse oximeter (Ohmeda, Louisville, Colorado, USA). The polysomnographic records were manually assessed using conventional criteria.²¹⁻²² Severity of sleep apnoea was assessed by the apnoea-hypopnoea index (AHI) and the minimum value of peripheral oxyhaemoglobin saturation. Hypopnoea was defined as a reduction of breathing during sleep with a decrease in oxyhaemoglobin saturation equal to or more than 3% from baseline or arousal.²³

MRS

Magnetic resonance imaging and MRS were performed with a Magnetom Vision with a standard circulatory polarised head coil operating at 1.5 T (Siemens, Erlangen, Germany). T1 weighted spin echo images were obtained in transverse, coronal, and sagittal directions. T2 weighted turbo spin echo images were obtained in a transverse direction. These MR images were used for anatomical localisation and screening for CNS abnormalities. Patients with abnormal MRI findings including brain infarction, haemorrhage, and white matter hyperintensity lesions were excluded from subsequent MRS examination, as metabolic changes due to OSA are indistinguishable from those caused by such

Table 1 Patient characteristics

No of patients	55
Age (y)	46.45 (12.64)
Men/women	49/6
Body mass index (kg/m ²)	28.76 (5.84)
Hypertension, yes	16 (29%)
Cardiac disease, yes	6 (11%)
Diabetes mellitus, yes	7 (13%)
Hyperlipidaemia, yes	8 (15%)
Apnoea-hypopnoea index (h)	43.78 (30.00)
SpO ₂ min (%)	73.40 (16.36)
N-acetylaspartate/choline ratio:	
Cerebral cortex	2.18 (0.36)
Cerebral white matter	1.85 (0.21)

Values are means (SD) unless indicated otherwise.

SpO₂ min=Minimum value of peripheral oxyhaemoglobin saturation.

CNS abnormalities. Patients with only periventricular rim, periventricular cap, or punctate lesions were included among those undergoing subsequent MRS examination.²⁴

The MRS examination and postprocessing were performed as described in detail previously.¹² Two dimensional chemical shift imaging studies²⁵ were performed using a 10 mm slice thickness with 16×16 phase encoding steps over a field of view of 160 mm in a transverse plane at the level of the bodies of the lateral ventricles. A volume of interest between 80×80 and 100×100 mm was selected within the field of view. We used a repetition time of 1500 ms and an echo time of 135 ms with two signal acquisitions for each phase step, resulting in a measurement time of 12 minutes 55 seconds. To achieve good static magnetic field homogeneity, we used multi-angle projection shim²⁶ combined with localised manual shimming of the volume of interest, resulting in a water resonance line width of 5-8 Hz (full width at half maximum). Magnetic resonance examinations were performed with patients awake.

After acquisition, spectral data were obtained using Luise software (Siemens). Peak areas for NAA (2.0 ppm), creatine (3.0 ppm), and choline (3.2 ppm) were calculated by fitting the spectrum to a sum of gaussian curves. The NAA/choline ratio was calculated from the peak areas. Results from voxels of roughly the anterior half of the volume of interest were discarded to avoid magnetic susceptibility effects. Results from voxels in columns on both ends of the volume of interest were discarded to avoid contamination of fat signal from the skull and scalp. The voxels mainly containing the medial aspects of the occipital and parietal lobes and cingulate gyrus (7 to 10 voxels) and those containing the posterior half of the periventricular white matter (8 to 12 voxels) were selected by visual inspection. The mean NAA/choline ratios for the cerebral cortex and those for the periventricular white matter were calculated separately from the selected voxels.

STATISTICS

Univariate analysis of variance (ANOVA) was used to determine main effects of candidate predictors including age, body mass index, AHI, the minimum value of peripheral oxyhaemoglobin saturation, the presence or absence of hypertension, cardiac disease, diabetes mellitus, and hyperlipidaemia on the NAA/choline




Figure 1 Representative spectra from (A) the cerebral cortex and (B) white matter of a patient with obstructive sleep apnoea. The chemical shift axis is displayed in ppm. The vertical axis is displayed in arbitrary units. Resonances of protons of N-acetylaspartate (2.0 ppm), creatine (3.0 ppm), and choline (3.2 ppm) are resolved.

ratios for the cerebral cortex and white matter and interactions between the candidate predictors. The level of significance was set at $p < 0.05$. Variables with a main effect of $p < 0.20$ in the univariate ANOVA were included in the multiple linear regression analyses for predicting the NAA/choline ratios for the cerebral cortex and white matter. The stepwise method based on F statistics was used for selection of variables for the final linear regression model. Entry and removal criteria were set at $p \leq 0.05$ and $p \geq 0.10$, respectively. SPSS for Windows (SPSS Japan, Tokyo, Japan) was used for statistical analyses.

Results

Eight patients (six men and two women; age range 59-74 years) with abnormal MRI findings were excluded from the MRS study. Thus, results for 55 patients (49 men and six women, age range 22-75 years; mean 46.45 (SD 12.64) years) were analyzed. The characteristics of the patients analyzed are summarised in table 1.

Representative spectra from the cerebral cortex and white matter are shown in figure 1.

Table 2 Univariate analyses of variance of candidate predictors for the NAA/choline ratios for the cerebral cortex and white matter

	df	NAA/choline _{cerebral cortex}		NAA/choline _{cerebral white matter}	
		F value	p Value	F value	p Value
Age	1, 38	14.597	<0.001	5.220	0.028
Sex*	1, 38	1.006	0.322	0.216	0.644
Body mass index	1, 38	0.656	0.423	1.096	0.302
Hypertension*	1, 38	1.829	0.184	4.111	0.0496
Cardiac disease	1, 38	0.056	0.814	1.887	0.178
Diabetes mellitus	1, 38	0.373	0.545	0.815	0.372
Hyperlipidaemia	1, 38	0.079	0.780	0.758	0.389
Apnoea-hypopnoea index	1, 38	0.001	0.980	7.195	0.011
SpO _{2 min}	1, 38	0.093	0.762	2.149	0.151

*The effect of sex×hypertension interaction on the NAA/choline ratio for the cerebral white matter was significant ($F(1, 38)=8.860, p=0.005$).

df=Degrees of freedom; SpO_{2 min}=minimum value of peripheral oxyhaemoglobin saturation.

Resonances of protons of NAA, creatine, and choline are resolved.

There was a significant main effect of age on the NAA/choline ratio for the cerebral cortex in the univariate ANOVA (table 2). No other significant main effect or interaction was found for the NAA/choline ratio for the cerebral cortex. Age and the presence or absence of hypertension were included in the multiple linear regression analysis. Age alone was selected for the final linear regression model predicting the NAA/choline ratio for the cerebral cortex. The regression equation was as follows:

$$\begin{aligned} \text{NAA/choline}_{\text{cortex}} &= -0.0158 \times \text{age (years)} + 2.92, \\ R &= 0.552, R^2 = 0.305, \text{ adjusted } R^2 = 0.292, \\ p &< 0.001 \text{ (fig 2)}. \end{aligned}$$

The main effects of age, AHI, and the presence or absence of hypertension and sex×hypertension interaction on the NAA/choline ratio for the cerebral white matter reached significance (table 2). These three variables, the minimum value of peripheral oxyhaemoglobin saturation, and the presence or absence of cardiac disease were included in the multiple linear regression analysis. The AHI, age, and the presence or absence of cardiac disease were selected for the final linear regression model for predicting the NAA/choline ratio for cerebral white matter. The regression equation was as follows:

$$\begin{aligned} \text{NAA/Choline}_{\text{white matter}} &= -0.00525 \times \text{age (years)} - 0.00277 \times \text{AHI} \\ & \text{(/hour)} - 0.194 \times \text{cardiac disease} + 2.23 \\ R &= 0.573, R^2 = 0.328, \text{ adjusted } R^2 = 0.289, \\ p &< 0.001; \end{aligned}$$

where the presence or absence of cardiac disease was coded 1 or 0, respectively (fig 3).




Figure 2 Relations between age and the NAA/chole ratios for the cerebral cortex (open circles) and white matter (closed triangles).




Figure 3 Relation between the apnoea-hypopnoea index (AHI) and the NAA/chole ratios for cerebral white matter.

Standardised partial regression coefficients for age, AHI, and the presence or absence of cardiac disease were -0.319 ($p=0.011$), -0.417 ($p<0.001$), and -0.300 ($p=0.014$), respectively. The relation between age and the NAA/chole ratio for cerebral white matter is shown in figure 2.

Discussion

We used the NAA/chole ratio as a metabolic indicator of cerebral impairment in this study. It is generally considered that NAA is solely of neuronal and axonal origin.^{27 28} Choline resonance is thought to originate mainly from phosphorylated cholines.²⁸ A decrease in NAA resonance is associated with neuronal loss, or axonal injury, or both.¹³⁻¹⁵ Changes in membrane metabolism and glial cell reaction may increase choline resonance.¹³⁻¹⁵ The NAA/chole ratio has been used as a sensitive indicator of cerebral metabolic impairment including neuronal loss, axonal injury, and gliosis.¹³⁻¹⁵

Age alone had a significant association with the NAA/chole ratio for the cerebral cortex on the univariate ANOVA and linear regression analysis. The NAA/chole ratio for the cerebral cortex decreased with increasing age. No significant relation was found between severity of OSA and the NAA/chole ratio for the cerebral cortex. Age, AHI, and the presence or absence of hypertension were significantly correlated with the NAA/chole ratio for periventricular white matter on univariate ANOVA.

However, AHI, age, and the presence or absence of cardiac disease were selected for the final linear regression model. The NAA/chole ratio for periventricular white matter decreased with increasing age and AHI and with the presence of cardiac disease. These findings indicate that an independent association exists between AHI and metabolic impairment in the periventricular white matter, which seems normal on the MRI of patients with OSA.

Arterial oxyhaemoglobin saturation may decrease during apnoea. A known mechanism of cerebral circulatory regulation increases cerebral blood flow in response to hypercapnia. Our results of MRS examination during sleep disclosed lactate production, indicating hypoxia causing anaerobic glycolysis, in the cerebral deep white matter of patients with moderate to severe OSA.¹⁶ This finding indicates that haemodynamic adjustment in the cerebral deep white matter may be not sufficient to compensate for a decrease in arterial oxyhaemoglobin saturation, and supports the hypothesis that cerebral hypoxia due to repeated sleep apnoeic episodes is responsible for the metabolic impairment seen in the cerebral deep white matter. However, the minimum value of oxyhaemoglobin saturation was not significantly related to the decrease in the NAA/chole ratio or the production of lactate.¹⁶ Results of several studies using transcranial Doppler sonography have indicated changes in cerebral circulatory adjustment in patients with OSA, including reduced cerebral blood flow velocity in response to obstructive sleep apnoeic episodes and altered cerebrovascular reactivity to hypercapnia.²⁹⁻³² These findings suggest that cerebral metabolic impairment due to OSA cannot be explained by a simple linear relation with arterial oxyhaemoglobin saturation.

The susceptibility of the cerebral deep white matter to OSA may be explainable in part by features of vessels in this region. Cerebral deep white matter is supplied via long small arteries and arterioles.³³ These vessels in white matter are subject to sclerotic changes, particularly in aged people.³⁴ In the cerebral deep white matter, the cerebrovascular reserve may not be sufficient to compensate for decreases in arterial oxyhaemoglobin saturation during repeated sleep apnoeic episodes.

Patients with OSA often have several comorbidities related to the cardiovascular system and metabolism including hypertension, cardiac diseases, and diabetes mellitus, which are thought to be cerebrovascular risk factors.¹⁷⁻¹⁹ Hypertension and diabetes mellitus are generally thought to accelerate arteriosclerosis.^{34 35} Cardiovascular and metabolic complications of OSA probably promote cerebral ischaemia, and play a part in the occurrence of metabolic impairment in the cerebral deep white matter. Our findings suggest that cerebrovascular risk factors may play a part in the occurrence of cerebral metabolic impairment.

Our finding of no significant relation between severity of OSA and the NAA/chole ratio for the cerebral cortex suggests that the

haemodynamic adjustment in the cerebral cortex may be sufficient to compensate for the decrease in arterial oxyhaemoglobin saturation during sleep apnoeic episodes. This finding may not hold true of other brain regions, such as the watershed areas and hippocampus. It is possible that an association existed between severity of OSA and the NAA/choline ratio for the cerebral cortex that was too weak to be detected in our study. The relatively large SD of the NAA/choline ratio for the cerebral cortex may to some extent be responsible for the lack of a relation between the severity of OSA and the NAA/choline ratio for this region. Incomplete separation of the cerebral cortex from white matter and CSF due to the low spatial resolution of our MRS examination may have resulted in considerable error in the determination of the NAA/choline ratio for the cerebral cortex. Further investigations are needed to determine the relation between severity of OSA and metabolic impairment in the cerebral cortex.

Many studies have shown cognitive and neuropsychological dysfunction in patients with OSA.^{1-6 9-11} Treatment with continuous positive airway pressure may improve these deficits, but not normalise them completely.^{4 5 9 10} Hypoxaemia during sleep and fragmentation of sleep are generally thought to play a part in causing these deficits.^{2-6 9} On the other hand, cerebral white matter lesions on MRI, which are generally thought to be related to chronic cerebral ischaemia, are often found in the aged, particularly those with hypertension or other cardiovascular or metabolic diseases.³⁵ Many studies have found a relation between cerebral white matter lesions and cognitive and neuropsychological dysfunction.^{36 37} Our MRS finding of metabolic impairment in the cerebral deep white matter may be related to cognitive and neuropsychological dysfunction in patients with OSA. Our results, however, failed to demonstrate an association of OSA with cortical degeneration. A comparative study of MRS and results of neuropsychological examinations is needed to determine the relation of cerebral metabolic impairment to cognitive and neuropsychological dysfunction in patients with OSA.

Because our study was cross sectional, the causal relation between OSA and the metabolic impairment in cerebral white matter cannot be determined from our results. Further investigations by longitudinal and experimental studies are needed to determine this.

In summary, our MRS findings indicate that a significant relation exists between AHI and the degree of metabolic impairment in cerebral white matter. Magnetic resonance spectroscopy may be useful for evaluation of CNS impairment in patients with OSA. Further investigation is needed to determine the relations between cerebral circulatory and metabolic impairment, and cognitive and neuropsychological dysfunction in patients with OSA.

This study was supported in part by a Special Coordination Fund for Promoting Science and Technology from The Science

and Technology Agency of Japan. Dr Kamba was supported by The Ministry of Education, Science, Sports and Culture of Japan and Konica Corporation.

- 1 Kales A, Caldwell AB, Cadioux RJ, et al. Severe obstructive sleep apnea, II: associated psychopathology and psychosocial consequences. *J Chronic Dis* 1985;38:427-34.
- 2 Findley LJ, Barth JT, Powers DC, et al. Cognitive impairment in patients with obstructive sleep apnea and associated hypoxemia. *Chest* 1986;90:686-90.
- 3 Greenberg GD, Watson RK, Deptula D. Neuropsychological dysfunction in sleep apnea. *Sleep* 1987;10:254-62.
- 4 Montplaisir J, Bédard MA, Richer F, et al. Neurobehavioral manifestations in obstructive sleep apnea syndrome before and after treatment with continuous positive airway pressure. *Sleep* 1992;15:S17-19.
- 5 Valencia-Flores M, Bliwise DL, Guilleminault C, et al. Cognitive function in patients with sleep apnea after acute nocturnal nasal continuous positive airway pressure (CPAP) treatment: sleepiness and hypoxemia effects. *J Clin Exp Neuropsychol* 1996;18:197-210.
- 6 Kim HC, Young T, Matthews CG, et al. Sleep-disordered breathing and neuropsychological deficits: a population-based study. *Am J Respir Crit Care Med* 1997;156:1813-9.
- 7 Carskadon MA, Dement WC, Mitler MM, et al. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. *Sleep* 1986;9:519-24.
- 8 Poceta JS, Timms RM, Jeong DU, et al. Maintenance of wakefulness test in obstructive sleep apnea syndrome. *Chest* 1992;101:893-7.
- 9 Walsleben JA, Squires NK, Rothenberger VL. Auditory event-related potentials and brain dysfunction in sleep apnea. *Electroencephalogr Clin Neurophysiol* 1989;74:297-311.
- 10 Rumbach L, Krieger J, Kurtz D. Auditory event-related potentials in obstructive sleep apnea: effects of treatment with nasal continuous positive airway pressure. *Electroencephalogr Clin Neurophysiol* 1991;80:454-7.
- 11 Sangal RB, Sangal JM. P300 latency: abnormal in sleep apnea with somnolence and idiopathic hypersomnia, but normal in narcolepsy. *Clin Electroencephalogr* 1995;26:146-53.
- 12 Kamba M, Suto Y, Ohta Y, et al. Cerebral metabolism in sleep apnea: evaluation by magnetic resonance spectroscopy. *Am J Respir Crit Care Med* 1997;156:296-8.
- 13 Larsson HBW, Christiansen P, Jensen M, et al. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis. *Magn Reson Med* 1991;22:23-31.
- 14 Meyerhoff DJ, Mackay S, Constans J-M, et al. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. *Ann Neurol* 1994;36:40-7.
- 15 van der Grond J, Balm R, Kappelle LJ, et al. Cerebral metabolism of patients with stenosis or occlusion of the internal carotid artery, a ¹H-MR spectroscopic imaging study. *Stroke* 1995;26:822-8.
- 16 Kamba M, Inoue Y, Higami S, et al. Changes in cerebral lactate metabolism in patients with obstructive sleep apnea [abstract]. *The Sixth World Congress on Sleep Apnea*. Sydney: 2000:68.
- 17 Young T, Peppard P, Palta M, et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. *Arch Intern Med* 1997;157:1746-52.
- 18 Peker Y, Kraiczki H, Hedner J, et al. An independent association between obstructive sleep apnoea and coronary artery disease. *Eur Respir J* 1999;14:179-84.
- 19 Katsumata K, Okada T, Miyao M, et al. High incidence of sleep apnea syndrome in a male diabetic population. *Diabetes Res Clin Pract* 1991;13:45-51.
- 20 Sappey-Mariniér, Angelié E, Meltz P, et al. Brain metabolic changes during normal aging detected by proton MR spectroscopic imaging [abstract]. *Proceedings of the Fourth Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine*. Berkeley, CA, USA: The International Society for Magnetic Resonance in Medicine, 1996:926.
- 21 Guilleminault C, Tilkian A, Dement WC. The sleep apnea syndromes. *Annu Rev Med* 1976;27:465-84.
- 22 Gastaut H, Tassinari CA, Duroc B. Etude polygraphique des manifestations épisodiques, (hypniques et respiratoires), diurnes et nocturnes, du syndrome de Pickwick. *Rev Neurol* 1965;112:568-79.
- 23 The American Academy of Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommendation for syndrome definition and measurement techniques in clinical research. *Sleep* 1999;22:667-89.
- 24 Chimowitz MI, Estes ML, Furlan AJ, et al. Further observations on the pathology of subcortical lesions identified on magnetic resonance imaging. *Arch Neurol* 1992;49:747-52.
- 25 Sauter R, Schneider M, Wicklow K, et al. Current status of clinically relevant techniques in magnetic resonance spectroscopy. *Electromedica* 1992;60:32-54.
- 26 Manabe A. Multi-angle projection shim (MAP shim): in vivo shim adjustment up to 2nd order with 0.2 second sequence time [abstract]. *Proceedings of the Second Annual Meeting of the Society for Magnetic Resonance* Berkeley, CA, USA: 1994:65.
- 27 Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in ¹H-NMR spectroscopic studies of brain. *Neurosci Biobehav Rev* 1989;13:23-31.
- 28 Miller BL. A review of chemical issues in ¹H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. *NMR Biomed* 1991;4:47-52.

- 29 Fischer AQ, Chaudhary BA, Taormina MA, *et al.* Intracranial hemodynamics in sleep apnea. *Chest* 1992;**102**:1402–6.
- 30 Bälfors EM, Franklin KA. Impairment of cerebral perfusion during obstructive sleep apneas. *Am J Respir Crit Care Med* 1994;**150**:1587–91.
- 31 Diomedes M, Placidi F, Cupini LM, *et al.* Cerebral hemodynamic changes in sleep apnea syndrome and effect of continuous positive airway pressure treatment. *Neurology* 1998;**51**:1051–6.
- 32 Netzer N, Werner P, Jochums I, *et al.* Blood flow of the middle cerebral artery with sleep-disordered breathing: correlation with obstructive hypopneas. *Stroke* 1998;**29**:87–93.
- 33 Moody DM, Bell MA, Challa VR. Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study. *Am J Neurodiol* 1990;**11**:431–9.
- 34 Furuta A, Ishii N, Nishihara Y, *et al.* Medullary arteries in aging and dementia. *Stroke* 1991;**22**:442–6.
- 35 Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis, a review. *Stroke* 1997;**28**:652–9.
- 36 Schmidt R, Fazekas F, Offenbacher H, *et al.* Neuropsychologic correlates of MRI white matter hyperintensities: a study of 150 normal volunteers. *Neurology* 1993;**43**:2490–4.
- 37 Ylikoski R, Ylikoski A, Erkinjuntti T, *et al.* White matter changes in healthy elderly persons correlate with attention and speed of mental processing. *Arch Neurol* 1993;**50**:818–24.

What's in the next issue

Future content

See which articles have just been accepted for publication and preview the table of contents for the next issue a month before it is published

www.jnnp.com



Cerebral metabolic impairment in patients with obstructive sleep apnoea: an independent association of obstructive sleep apnoea with white matter change

M Kamba, Y Inoue, S Higami, Y Suto, T Ogawa and W Chen

J Neurol Neurosurg Psychiatry 2001 71: 334-339
doi: 10.1136/jnp.71.3.334

Updated information and services can be found at:
<http://jnp.bmj.com/content/71/3/334>

	<i>These include:</i>
References	This article cites 34 articles, 8 of which you can access for free at: http://jnp.bmj.com/content/71/3/334#BIBL
Email alerting service	Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections	Articles on similar topics can be found in the following collections Hypertension (380) Radiology (1747) Radiology (diagnostics) (1309) Drugs: CNS (not psychiatric) (1945) Sleep disorders (143) Sleep disorders (neurology) (151)
--------------------------	---

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>